비용종을 동반한 만성 비부비동염 치료에서 생물학적 제제의 최신 지견

키워드

참고문헌 (47)

1. Ahn JC, "Prevalence and risk factors of chronic rhinosinusitus, allergic rhinitis, and nasal septal deviation:Results of the Korean National Health and Nutrition Survey 2008-2012", JAMA Otolaryngol Head Neck Surg, 142(2), pp.162~167 (2016)
2. Fokkens WJ, "EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists", Rhinology, 50(1), pp.1~12 (2012)
3. Benjamin MR, "Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting", J Allergy Clin Immunol Pract, 7(3), pp.1010~1016 (2019)
4. Loftus CA, "Revision surgery rates in chronic rhinosinusitis with nasal polyps : Meta-analysis of risk factors", Int Forum Allergy Rhinol, 10(2), pp.199~207 (2020)
5. Busse WW, "Anti-immunoglobulin E(omalizumab)therapy in allergic asthma", Am J Respir Crit Care Med, 164(8 Pt 2), pp.S12~S17 (2001)
6. Pauwels B, "Emerging biologics for the treatment of chronic rhinosinusitis", Expert Rev Clin Immunol, 11(3), pp.349~361 (2015)
7. Fajt ML, "Biologic therapy in asthma : Entering the new age of personalized medicine", J Asthma, 51(7), pp.669~676 (2014)
8. Langdon C, "Nasal polyps in patients with asthma:Prevalence, impact, and management challenges", J Asthma Allergy, 9, pp.45~53 (2016)
9. Fokkens WJ, "EUFOREA consensus on biologics for CRSwNP with or without asthma", Allergy, 74(12), pp.2312~2319 (2019)
10. 송윤재, "비용종을 동반한 만성 비부비동염의 바이오마커: 내재형에 기초한 맞춤의료", 대한이비인후-두경부외과학회지, 62(8), pp.427~434 (2019), 대한이비인후과학회
11. Bachert C, "Biotherapeutics in chronic rhinosinusitis with and without nasal polyps", J Allergy Clin Immunol Pract, 5(6), pp.1512~1516 (2017)
12. Huang Z, "Peripheral blood T-helper cells and eosinophil populations in patients with atopic and nonatopic chronic rhinosinusitis", Am J Rhinol Allergy, 31(1), pp.8~12 (2017)
13. Akdis CA, "Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology", J Allergy Clin Immunol, 131(6), pp.1479~1490 (2013)
14. Poposki JA, "Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps", Immun Inflamm Dis, 5(3), pp.233~243 (2017)
15. Mahdavinia M, "Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia", J Allergy Clin Immunol, 135(2), pp.576~579 (2015)
16. 양정환, "내재형에 따른 비용종을 동반한 만성 비부비동염의 새로운 병태생리", 대한이비인후-두경부외과학회지, 60(9), pp.431~436 (2017), 대한이비인후과학회[DOI]
17. Hong CJ, "Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis : A systematic review", Syst Rev, 4, pp.166~ (2015)
18. Gevaert P, "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma", J Allergy Clin Immunol, 131(1), pp.110~116 (2013)
19. Pinto JM, "A randomized, double-blind, placebo-controlled trial of antiIgE for chronic rhinosinusitis", Rhinology, 48(3), pp.318~324 (2010)
20. Bachert C, "Endotype-driven care pathways in patients with chronic rhinosinusitis", J Allergy Clin Immunol, 141(5), pp.1543~1551 (2018)
21. Busse W, "Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma", J Allergy Clin Immunol, 108(2), pp.184~190 (2001)
22. Gevaert P, "Efficacy and safety of omalizumab in nasal polyposis : 2 randomized phase 3 trials", J Allergy Clin Immunol, 146(3), pp.595~605 (2020)
23. Dennis SK, "A review of classification schemes for chronic rhinosinusitis with nasal polyposis endotypes", Laryngoscope Investig Otolaryngol, 1(5), pp.130~134 (2016)
24. Tomassen P, "Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers", J Allergy Clin Immunol, 137(5), pp.1449~1456 (2016)
25. Kim C, "Role of biologics in chronic rhinosinusitis with nasal polyposis : State of the art review", Otolaryngol Head Neck Surg, 164(1), pp.57~66 (2021)
26. Gevaert P, "Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps", J Allergy Clin Immunol, 118(5), pp.1133~1141 (2006)
27. Gevaert P, "Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis", J Allergy Clin Immunol, 128(5), pp.989~995.e1-8 (2011)
28. Bachert C, "Reduced need for surgery in severe nasal polyposis with mepolizumab : Randomized trial", J Allergy Clin Immunol, 140(4), pp.1024~1031.e14 (2017)
29. Han JK, "Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Respir Med, 9(10), pp.1141~1153 (2021)
30. Bakhshaee M, "The presence of fungal-specific IgE in serum and sinonasal tissue among patients with sinonasal polyposis", Eur Arch Otorhinolaryngol, 271(11), pp.2871~2875 (2014)
31. Kariyawasam HH, "Dupilumab : Clinical efficacy of blocking IL-4", IL-13 signalling in chronic rhinosinusitis with nasal polyps, 2020, pp.14, 1757~1769
32. Bachert C, "Current and future treatment options for adult chronic rhinosinusitis : Focus on nasal polyposis", J Allergy Clin Immunol, 136(6), pp.1431~1440 (2015)
33. Bachert C, "Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis : A randomized clinical trial", JAMA, 315(5), pp.469~479 (2016)
34. Bachert C, "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials", Lancet, 394(10209), pp.1638~1650 (2019)
35. Hellings PW, "State-of-the-art overview on biological treatment for CRSwNP", Rhinology, 59(2), pp.151~163 (2021)
36. Nagarkar DR, "Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis", J Allergy Clin Immunol, 132(3), pp.593~600 (2013)
37. Wang WW, "TSLP regulates eotaxin-1 production by nasal epithelial cells from patients with eosinophilic CRSwNP", Rhinology, 56(4), pp.370~377 (2018)
38. Liu T, "Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis", Am J Med Sci, 341(1), pp.40~47 (2011)
39. Corren J, "Tezepelumab in adults with uncontrolled asthma", N Engl J Med, 377(10), pp.936~946 (2017)
40. Kim DK, "The role of interleukin-33 in chronic rhinosinusitis", Thorax, 72(7), pp.635~645 (2017)
41. Song W, "IL-33 expression in chronic rhinosinusitis with nasal polyps and its relationship with clinical severity", ORL J Otorhinolaryngol Relat Spec, 79(6), pp.323~330 (2017)
42. Luo X, "Interleukin-33promotes Th2", Th17 response in eosinophilic and non-eosinophilic nasal polyps, 2020, pp.82(1), 34~39
43. Fokkens WJ, "Executive summary of EPOS 2020 including integrated care pathways", Rhinology, 58(2), pp.82~111 (2020)
44. Castro M, "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma", N Engl J Med, 378(26), pp.2486~2496 (2018)
45. Farne HA, "Anti-IL5 therapies for asthma", Cochrane Database Syst Rev, (9), pp.CD010834~ (2017)
46. Rabe KF, "Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma", N Engl J Med, 378(26), pp.2475~2485 (2018)
47. Bidder T, "Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study", Rhinology, 56(1), pp.42~45 (2018)

관련 논문AI추천